Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.5 USD | -3.77% | -3.96% | +59.60% |
05-10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
05-09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.60% | 1.7B | |
+64.09% | 62.59B | |
-1.70% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.80% | 26.21B | |
-21.72% | 19.09B | |
+4.38% | 13.08B | |
+25.58% | 12.26B | |
+28.42% | 12.05B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial